Cargando…

Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study

BACKGROUND: Clinical inertia can lead to poor glycemic control among type 2 diabetes patients. However, there is paucity of information on clinical inertia in low- and middle-income countries including Malaysia. This study aimed to determine the time to treatment intensification among T2D patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Kim Sui, Moy, Foong Ming, Mohd Yusof, Khalijah, Mustapha, Feisul Idzwan, Mohd Ali, Zainudin, Hairi, Noran Naqiah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546487/
https://www.ncbi.nlm.nih.gov/pubmed/33035261
http://dx.doi.org/10.1371/journal.pone.0240531
_version_ 1783592238920499200
author Wan, Kim Sui
Moy, Foong Ming
Mohd Yusof, Khalijah
Mustapha, Feisul Idzwan
Mohd Ali, Zainudin
Hairi, Noran Naqiah
author_facet Wan, Kim Sui
Moy, Foong Ming
Mohd Yusof, Khalijah
Mustapha, Feisul Idzwan
Mohd Ali, Zainudin
Hairi, Noran Naqiah
author_sort Wan, Kim Sui
collection PubMed
description BACKGROUND: Clinical inertia can lead to poor glycemic control among type 2 diabetes patients. However, there is paucity of information on clinical inertia in low- and middle-income countries including Malaysia. This study aimed to determine the time to treatment intensification among T2D patients with HbA1c of ≥7% (≥53 mmol/mol) in Malaysian public health clinics. The proportion of patients with treatment intensification and its associated factors were also determined. MATERIAL AND METHODS: This was a five-year retrospective open cohort study using secondary data from the National Diabetes Registry. The study setting was all public health clinics (n = 47) in the state of Negeri Sembilan, Malaysia. Time to treatment intensification was defined as the number of years from the index year until the addition of another oral antidiabetic drug or initiation of insulin. Life table survival analysis based on best-worst case scenarios was used to determine the time to treatment intensification. Discrete-time proportional hazards model was fitted for the factors associated with treatment intensification. RESULTS: The mean follow-up duration was 2.6 (SD 1.1) years. Of 7,646 patients, the median time to treatment intensification was 1.29 years (15.5 months), 1.58 years (19.0 months) and 2.32 years (27.8 months) under the best-, average- and worst-case scenarios respectively. The proportion of patients with treatment intensification was 45.4% (95% CI: 44.2–46.5), of which 34.6% occurred only after one year. Younger adults, overweight, obesity, use of antiplatelet medications and poorer HbA1c were positively associated with treatment intensification. Patients treated with more oral antidiabetics were less likely to have treatment intensification. CONCLUSION: Clinical inertia is present in the management of T2D patients in Malaysian public health clinics. We recommend further studies in lower- and middle-income countries to explore its causes so that targeted strategies can be developed to address this issue.
format Online
Article
Text
id pubmed-7546487
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-75464872020-10-19 Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study Wan, Kim Sui Moy, Foong Ming Mohd Yusof, Khalijah Mustapha, Feisul Idzwan Mohd Ali, Zainudin Hairi, Noran Naqiah PLoS One Research Article BACKGROUND: Clinical inertia can lead to poor glycemic control among type 2 diabetes patients. However, there is paucity of information on clinical inertia in low- and middle-income countries including Malaysia. This study aimed to determine the time to treatment intensification among T2D patients with HbA1c of ≥7% (≥53 mmol/mol) in Malaysian public health clinics. The proportion of patients with treatment intensification and its associated factors were also determined. MATERIAL AND METHODS: This was a five-year retrospective open cohort study using secondary data from the National Diabetes Registry. The study setting was all public health clinics (n = 47) in the state of Negeri Sembilan, Malaysia. Time to treatment intensification was defined as the number of years from the index year until the addition of another oral antidiabetic drug or initiation of insulin. Life table survival analysis based on best-worst case scenarios was used to determine the time to treatment intensification. Discrete-time proportional hazards model was fitted for the factors associated with treatment intensification. RESULTS: The mean follow-up duration was 2.6 (SD 1.1) years. Of 7,646 patients, the median time to treatment intensification was 1.29 years (15.5 months), 1.58 years (19.0 months) and 2.32 years (27.8 months) under the best-, average- and worst-case scenarios respectively. The proportion of patients with treatment intensification was 45.4% (95% CI: 44.2–46.5), of which 34.6% occurred only after one year. Younger adults, overweight, obesity, use of antiplatelet medications and poorer HbA1c were positively associated with treatment intensification. Patients treated with more oral antidiabetics were less likely to have treatment intensification. CONCLUSION: Clinical inertia is present in the management of T2D patients in Malaysian public health clinics. We recommend further studies in lower- and middle-income countries to explore its causes so that targeted strategies can be developed to address this issue. Public Library of Science 2020-10-09 /pmc/articles/PMC7546487/ /pubmed/33035261 http://dx.doi.org/10.1371/journal.pone.0240531 Text en © 2020 Wan et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wan, Kim Sui
Moy, Foong Ming
Mohd Yusof, Khalijah
Mustapha, Feisul Idzwan
Mohd Ali, Zainudin
Hairi, Noran Naqiah
Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study
title Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study
title_full Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study
title_fullStr Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study
title_full_unstemmed Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study
title_short Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study
title_sort clinical inertia in type 2 diabetes management in a middle-income country: a retrospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546487/
https://www.ncbi.nlm.nih.gov/pubmed/33035261
http://dx.doi.org/10.1371/journal.pone.0240531
work_keys_str_mv AT wankimsui clinicalinertiaintype2diabetesmanagementinamiddleincomecountryaretrospectivecohortstudy
AT moyfoongming clinicalinertiaintype2diabetesmanagementinamiddleincomecountryaretrospectivecohortstudy
AT mohdyusofkhalijah clinicalinertiaintype2diabetesmanagementinamiddleincomecountryaretrospectivecohortstudy
AT mustaphafeisulidzwan clinicalinertiaintype2diabetesmanagementinamiddleincomecountryaretrospectivecohortstudy
AT mohdalizainudin clinicalinertiaintype2diabetesmanagementinamiddleincomecountryaretrospectivecohortstudy
AT hairinorannaqiah clinicalinertiaintype2diabetesmanagementinamiddleincomecountryaretrospectivecohortstudy